BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17825299)

  • 1. The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2.
    Lolkema MP; Mans DA; Snijckers CM; van Noort M; van Beest M; Voest EE; Giles RH
    FEBS Lett; 2007 Oct; 581(24):4571-6. PubMed ID: 17825299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mobility of the von Hippel-Lindau tumour suppressor protein is regulated by kinesin-2.
    Mans DA; Lolkema MP; van Beest M; Daenen LG; Voest EE; Giles RH
    Exp Cell Res; 2008 Apr; 314(6):1229-36. PubMed ID: 18261724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development.
    Kuehn EW; Walz G; Benzing T
    Cancer Res; 2007 May; 67(10):4537-40. PubMed ID: 17510376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth.
    Schermer B; Ghenoiu C; Bartram M; Müller RU; Kotsis F; Höhne M; Kühn W; Rapka M; Nitschke R; Zentgraf H; Fliegauf M; Omran H; Walz G; Benzing T
    J Cell Biol; 2006 Nov; 175(4):547-54. PubMed ID: 17101696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic deletion of the long isoform of the von Hippel-Lindau tumour suppressor gene product alters microtubule dynamics.
    Frew IJ; Smole Z; Thoma CR; Krek W
    Eur J Cancer; 2013 Jul; 49(10):2433-40. PubMed ID: 23541568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.
    Hergovich A; Lisztwan J; Barry R; Ballschmieter P; Krek W
    Nat Cell Biol; 2003 Jan; 5(1):64-70. PubMed ID: 12510195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3.
    Hergovich A; Lisztwan J; Thoma CR; Wirbelauer C; Barry RE; Krek W
    Mol Cell Biol; 2006 Aug; 26(15):5784-96. PubMed ID: 16847331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
    Nyhan MJ; O'Sullivan GC; McKenna SL
    Biochem Soc Trans; 2008 Jun; 36(Pt 3):472-8. PubMed ID: 18481984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The von hippel-lindau tumor suppressor protein: an update.
    Kaelin WG
    Methods Enzymol; 2007; 435():371-83. PubMed ID: 17998064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design.
    Liu J; Nussinov R
    Proc Natl Acad Sci U S A; 2008 Jan; 105(3):901-6. PubMed ID: 18195360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network.
    Thoma CR; Frew IJ; Hoerner CR; Montani M; Moch H; Krek W
    Nat Cell Biol; 2007 May; 9(5):588-95. PubMed ID: 17450132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pVHL: a multipurpose adaptor protein.
    Frew IJ; Krek W
    Sci Signal; 2008 Jun; 1(24):pe30. PubMed ID: 18560019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability.
    Thoma CR; Matov A; Gutbrodt KL; Hoerner CR; Smole Z; Krek W; Danuser G
    J Cell Biol; 2010 Sep; 190(6):991-1003. PubMed ID: 20855504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
    Kaelin WG
    Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Hippel-Lindau disease.
    Kaelin WG
    Annu Rev Pathol; 2007; 2():145-73. PubMed ID: 18039096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance.
    Thoma CR; Frew IJ; Krek W
    Cell Cycle; 2007 Aug; 6(15):1809-13. PubMed ID: 17671433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VHL loss causes spindle misorientation and chromosome instability.
    Thoma CR; Toso A; Gutbrodt KL; Reggi SP; Frew IJ; Schraml P; Hergovich A; Moch H; Meraldi P; Krek W
    Nat Cell Biol; 2009 Aug; 11(8):994-1001. PubMed ID: 19620968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into the molecular features of the von Hippel-Lindau-like protein.
    Minervini G; Quaglia F; Tabaro F; Tosatto SCE
    Amino Acids; 2019 Nov; 51(10-12):1461-1474. PubMed ID: 31485743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
    Turcotte S; Desrosiers RR; Beliveau R
    Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.